This Week in Addiction Medicine from ASAM

American Society of Addiction Medicine
  • 4,9 (7)
  • MÉDECINE
  • CHAQUE SEMAINE
This Week in Addiction Medicine from ASAM

A podcast source for news briefings on the top stories in the field of addiction medicine.

  1. -4 J

    Lead: Cannabis Use Disorder Emergency Department Visits and Hospitalizations and 5-Year Mortality

    Cannabis Use Disorder Emergency Department Visits and Hospitalizations and 5-Year Mortality JAMA Network Open This cohort study of 11.6 million people who were studied for a median of five years investigated if individuals who have hospital-based (emergency department or hospitalization) care for a cannabis use disorder (CUD) were at increased risk of death. Researchers found that individuals with incident hospital-based care for a CUD were at a 2.8-fold increased risk of death within five years relative to the general population. These results suggest that individuals who require hospital-based care for a CUD may be at increased risk of premature death.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

    6 min

  2. 11 FÉVR.

    Lead: Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders

    Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders American Journal of Psychiatry A commonly held model of addiction posits that as addictions develop, there is progression from positive reinforcement to negative reinforcement to ameliorate withdrawal symptoms. In this study, researchers examined the subjective response to alcohol among persons with and without alcohol use disorder (AUD) and with or without comorbid depression. Regardless of the presence of comorbid depression, persons with AUD reported pleasurable effects, including stimulation and hedonic reward, after consumption of alcohol. In contrast, among those without AUD, the positive effects were less substantial. Participants did report reduction in negative affect, but the effects were relatively small. These findings suggest that positive reinforcement is sustained in the progression of AUD and the reward-sensitive stage may exist along with negative reinforcement.    Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

    7 min

  3. 4 FÉVR.

    Lead: Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl

    Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl JAMA Network Open The accumulation of fentanyl in fat is likely responsible for the risk of precipitated withdrawal when buprenorphine is initiated. Low dose initiation (LDI) of buprenorphine attempts to minimize this risk. This retrospective study included 126 individuals making 175 LDI attempts in an outpatient setting. Patients chose either a 4 day or 7 day LDI protocol with buprenorphine monoproduct. Both protocols begin with buprenorphine 0.5mg, increasing to 8mg tid. Overall LDI was successful in 34% of attempts (with no difference between the protocols) and one month retention on buprenorphine was 21%. Repeated LDI attempts were less likely to be successful (second attempt aOR 0.3). Unhoused people had lower odds of success (OR 0.4). The authors conclude that people with OUD using fentanyl attempting outpatient LDI of buprenorphine had low odds of success.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

    7 min

  4. 28 JANV.

    Lead: Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning

    Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning JAMA Psychiatry This longitudinal cohort study examined the association of state-level medical and recreational cannabis laws with cannabis use disorder (CUD) and cannabis poisonings in the adult population with employer-sponsored health insurance. The study showed that from 2011 to 2021, states with legalized medical cannabis experienced 42.7% and 88.6% increases in CUD and cannabis poisoning, respectively, compared to states without legalized medical cannabis. States with legalized recreational cannabis experienced a 31.6% increase in cannabis poisoning compared to states without legalized recreational cannabis. Thus, state medical cannabis legalization was associated with increased CUD and cannabis poisonings, and state recreational cannabis legalization was associated with increased cannabis poisoning in the adult population with employer-sponsored health insurance.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

    5 min

  5. 21 JANV.

    Lead: Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice

    Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice American Journal of Psychiatry This narrative review discusses five clinically relevant and prevalent behavioral addictions that are common and often co-occur with psychiatric disorders such as depression and anxiety. Gambling disorder is the only behavioral addiction recognized as a clinical disorder in DSM-5, and Internet gaming disorder is included as a condition requiring further research. ICD-11 categorizes gambling and gaming disorders as disorders due to addictive behaviors. Additional behavioral addictions may include compulsive sexual behavior disorder, compulsive buying-shopping disorder, and problematic use of social media. Validated diagnostic instruments exist, with empirical support varying across conditions. No medications have approved indications from regulatory bodies for behavioral addictions, and cognitive-behavioral therapy has the most empirical support for efficacious treatment. Treatment optimization involving pharmacotherapy, psychotherapy, neuromodulation, and their combination warrants additional investigation.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

    6 min

  6. 14 JANV.

    ASAM Weekly Special Episode: Dr. David Fiellin & Dr. Eric Strain sit down to discuss the concept of Treatment Refractory Addiction

    Host Dr. Nick Athanasiou is joined by Dr. David Fiellin and Dr. Eric Strain to discuss the concept of Treatment Refractory Addiction.  Why does the field of addiction medicine need this term, how is it defined and how the current treatment system aligns with the idea? Listen to the full interview to learn more!   Treatment Failure Versus Failed Treatments: The Risks of Embracing Treatment Refractory Addiction [Dr. David Fiellin] The Concept of Treatment-Refractory Addiction: A Call to the Field [Dr. Eric Strain] The Concept of Treatment-Refractory Addiction: Implications for Addiction Treatment Systems and Research [Dr. Edward Nunes & Dr. Thomas McLellan] - Subscribe to the ASAM Weekly

    27 min

  7. 14 JANV.

    Lead: Review of Evidence on Alcohol and Health

    Review of Evidence on Alcohol and Health National Academies of Sciences, Engineering, and Medicine To inform the next edition of the Dietary Guidelines for Americans (DGA), Congress tasked the National Academies with convening an expert committee to independently review the evidence on the relationship between moderate alcohol consumption and eight health outcomes including obesity, cancer, and cardiovascular disease. This controversial report found that a pattern of moderate drinking was associated with 18 percent fewer cardiovascular disease deaths, a 16 percent lower risk of all-cause mortality, and a 10 percent heightened risk of breast cancer for women.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

    7 min

  8. 17/12/2024

    Lead: The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies

    The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies Psychological Medicine Using data from the EU-GEI case-control study and UK Biobank, researchers examined the independent and combined effect of heavy cannabis use and schizophrenia polygenic risk score (PRS), on risk for psychosis. Schizophrenia PRS and cannabis use independently increased risk of psychosis. Schizophrenia PRS was not associated with patterns of cannabis use. It was associated with lifetime and daily cannabis use without psychosis, but the effect was substantially reduced when cannabis use disorder (CUD) PRS was included in the model. Regular users of high-potency cannabis had the highest odds of being a case independently of schizophrenia PRS. Regular use of high-potency cannabis remains a strong predictor of psychotic disorder, independent of schizophrenia PRS. Schizophrenia PRS does not seem to be associated with heavy cannabis use. These are important findings, at a time of increasing use and potency of cannabis worldwide.    Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

    8 min
Tout afficher (100)

Notes et avis

4,9
sur 5
7 notes

À propos

A podcast source for news briefings on the top stories in the field of addiction medicine.

Informations

  • Création
    American Society of Addiction Medicine
  • Années d’activité
    2022 - 2025
  • Épisodes
    100
  • Classification
    Tous publics
  • Copyright
    © Copyright 2022. All rights reserved.
  • Site web de l’émission
    This Week in Addiction Medicine from ASAM

Vous aimeriez peut‑être aussi

Pour écouter des épisodes au contenu explicite, connectez‑vous.

Recevez les dernières actualités sur cette émission

Connectez‑vous ou inscrivez‑vous pour suivre des émissions, enregistrer des épisodes et recevoir les dernières actualités.
Choisissez un pays ou une région

Afrique, Moyen‑Orient et Inde

Asie‑Pacifique

Europe

Amérique latine et Caraïbes

États‑Unis et Canada